7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 
      
    		                                            
      cash flows from operating activities:
    		                                            
      net income
    		26,013,000 -4,708,000 -43,773,000 -55,982,000 -76,616,000 -21,854,000 -21,398,000 -11,296,000 -10,861,000 -8,475,000 -8,356,000 -5,486,000 -6,132,000 -6,725,000 -5,724,000 -2,828,000 -8,140,000 -10,988,000 -8,954,000 -2,852,000 -8,545,000 -7,384,000 -5,858,000 -14,625,000 889,000 -10,008,000 -7,030,000 263,000 -2,206,000 -7,637,000 -3,755,000 -5,025,425 -3,786,000 -3,969,000 -2,887,000 -2,613,214 -2,750,000 -3,513,000 -3,189,000 -2,844,546 -3,294,000 1,881,000 -11,651,000 -7,855,513 
      adjustments to reconcile net income to net cash from operating activities:
    		                                            
      depreciation and amortization
    		502,000 502,000 504,000 503,000 500,000 494,000 490,000 489,000 490,000 489,000 490,000 488,000 492,000 492,000 492,000 492,000 492,000 490,000 489,000 488,000 489,000 488,000 489,000 490,000 490,000 489,000 489,000 490,000 490,000 491,000 492,000 582,271 459,000 419,000 151,000 37,640 39,000 35,000 20,000 60,228 17,000 16,000 15,000 8,516 
      accretion of premium/discount on marketable securities
    		-371,000 -974,000 -980,000 -1,400,000 -1,909,000                                        
      non-cash lease expense
    		120,000 169,000 195,000  111,000 70,000 69,000  67,000 109,000 78,000  73,000 71,000 71,000  69,000 75,000 76,000                          
      amortization of debt issuance costs
    		9,000 9,000 8,000                                          
      stock-based compensation expense
    		9,998,000 9,698,000 14,679,000 29,755,000 56,598,000 7,160,000 6,445,000 1,909,000 2,201,000 1,204,000 631,000 632,000 683,000 571,000 644,000 418,000 906,000 857,000 1,095,000 393,000 374,000 341,000 392,000 295,000 153,000 175,000 202,000 257,000 211,000 179,000 341,000 25,031 227,000 443,000 185,000 311,270 206,000 218,000 136,000 196,369 144,000 201,000 401,000 324,435 
      change in fair value of contingent consideration
    		614,000 1,101,000 2,967,000 327,000 877,000 1,637,000 401,000 1,081,000 1,021,000 313,000 299,000 -602,000 132,000 616,000 -858,000 -3,329,000 551,000 3,034,000 -987,000 140,000 774,000 2,842,000 584,000 -128,000 28,000 183,000 206,000 -22,000 228,000 -67,000 428,000    5,000  8,000 8,000 19,000      
      other non-cash reconciling items
    		14,000 12,000 4,000  -1,000 -1,000 -1,000    16,000  -1,000 1,000 -2,000                              
      change in operating assets and liabilities:
    		                                            
      accounts receivable
    		-882,000                                  23,000 3,790 151,000 -101,000 -31,000 -62,127 -82,000 -4,000 -8,000 37,605 
      inventory
    		-3,916,000                                 32,000 -195,000 42,617 71,000 -121,000 -102,000      
      prepaid expenses, other current assets and other assets
    		-948,000 3,077,000 -3,416,000 -1,029,000 -101,000 299,000 81,000 -660,000 113,000 44,000 -334,000 -224,000 3,000 220,000 114,000   -15,000 98,000 -671,000 157,000 126,000 -161,000                      
      accounts payable
    		1,929,000 733,000 -3,336,000 2,578,000 2,527,000 -4,298,000 4,865,000 34,000 -341,000 678,000 1,001,000 -547,000 -82,000 198,000 -1,046,000 -604,000 522,000 -1,333,000 1,180,000 279,000 -404,000 134,000 1,485,000 260,000 -5,000 482,000 324,000 -363,000 264,000 -61,000 409,000 -41,370 -38,000 445,000 -175,000 -324,163 -159,000 -293,000 627,000 -330,055 141,000 202,000 199,000 250,897 
      accrued compensation
    		981,000 1,990,000 -499,000 1,368,000 1,259,000 923,000 -1,909,000 1,637,000 333,000 444,000 -954,000 393,000 350,000 334,000 -130,000 -81,000 157,000 241,000 -594,000 249,000 236,000 182,000 55,000                      
      operating lease liabilities
    		-115,000 -34,000 -40,000 -31,000 -45,000 -51,000 -56,000 -67,000 -15,000 -111,000 -116,000 -84,000 -98,000 -86,000 -34,000 -107,000 12,000 -86,000 -82,000 -81,000 -217,000 -17,000 10,000                      
      other liabilities
    		9,543,000 2,497,000 937,000 -341,000 1,975,000 -385,000 -44,000 805,000 237,000 -179,000 208,000 -187,000 256,000 55,000 37,000 -164,000 237,000 21,000 41,000 -170,000 255,000 -105,000 -157,000                      
      net cash from operating activities
    		43,454,000 -12,608,000 -32,752,000 -23,991,000 -14,926,000 -17,651,000 -12,528,000 -6,314,000 -6,332,000 -5,566,000 -6,728,000 -5,143,000 -4,656,000 -4,620,000 -6,362,000 -6,863,000 -5,406,000 -8,013,000 -7,488,000 -6,867,000 -6,164,000 -6,534,000 -5,659,000 -5,076,000 -4,719,000 -3,893,000 -3,687,000 -3,736,000 -2,677,000 -2,750,000 -2,520,000 -2,731,958 -2,271,000 -2,764,000 -2,183,000 -2,687,980 -2,786,000 -4,040,000 -3,984,000 -3,378,330 -2,861,000 -2,251,000 -1,809,000 -1,556,362 
      capex
    		-1,000 -9,000 -5,000 -8,000 -191,000 -8,000 -3,000 0 0 0 0 -6,000 0 0 0 -13,000 -5,000 0 -4,000 -6,000 0 0 0 -5,000 0 -6,000 -10,000 -2,000 -5,000 0 0 1,431 0 0 -4,000 320 0 -20,000 -19,000 -7,777 -32,000 -15,000 -1,000 0 
      free cash flows
    		43,453,000 -12,617,000 -32,757,000 -23,999,000 -15,117,000 -17,659,000 -12,531,000 -6,314,000 -6,332,000 -5,566,000 -6,728,000 -5,149,000 -4,656,000 -4,620,000 -6,362,000 -6,876,000 -5,411,000 -8,013,000 -7,492,000 -6,873,000 -6,164,000 -6,534,000 -5,659,000 -5,081,000 -4,719,000 -3,899,000 -3,697,000 -3,738,000 -2,682,000 -2,750,000 -2,520,000 -2,730,527 -2,271,000 -2,764,000 -2,187,000 -2,687,660 -2,786,000 -4,060,000 -4,003,000 -3,386,107 -2,893,000 -2,266,000 -1,810,000 -1,556,362 
      cash flows from investing activities:
    		                                            
      purchases of property and equipment
    		-1,000 -9,000 -5,000 -8,000 -191,000 -8,000 -11,000     -6,000 0   -13,000 -5,000 0 -4,000 -4,000    -5,000 0 -6,000 -10,000 -2,000 -5,000                
      purchases of marketable securities
    		-163,172,000 -59,406,000 -45,358,000 -47,549,000 -47,769,000 -145,913,000 -115,233,000                                      
      maturities of marketable securities
    		71,730,000 51,500,000 68,300,000 54,000,000 52,000,000                                        
      net cash from investing activities
    		-91,443,000 -7,915,000 22,937,000 6,443,000 4,040,000 -120,921,000 -115,244,000     -6,000 0   -13,000 -5,000 0 -4,000 -4,000    103,000 441,000 -6,000 -10,000     239,782 371,000 -228,000 -4,000 320 0 -20,000 -19,000 -31,777 -1,258,000 -30,000 -1,000  
      cash flows from financing activities:
    		                                            
      proceeds from the sale of common stock, net of issuance costs
    		   0 0                                        
      payment of debt issuance costs
    		0 0 -62,000                                          
      proceeds from exercise of common stock warrants
    		0 2,176,000 3,011,000    923,000                                      
      proceeds from exercise of common stock warrants and pre-funded common stock warrants, net of costs
    		                                            
      proceeds received prior to and for the issuance of common stock and pre-funded warrants
    		                                            
      proceeds from exercise of stock options
    		2,255,000 13,724,000 269,000 -1,000 765,000 537,000 15,000                                      
      tax withholding payments for net share-settled equity awards
    		0           0 0 0 -16,000 0 0 0 -120,000                          
      net cash from financing activities
    		218,154,000 15,689,000 3,218,000 57,063,000 2,275,000 152,749,000 938,000 123,558,000 39,401,000   0 342,000 -282,000 14,032,000 -5,000 0 2,000 -125,000 -42,000 -195,000 53,963,000 -4,000     16,302,000 700,000 537,000 288,000 13,944,687 0 0 10,000,000 -867 5,699,000 70,000 5,000,000 4,184,920 1,309,000 282,000 3,382,000 9,479,985 
      net increase in cash and cash equivalents
    		   39,515,000 -8,611,000   117,244,000 33,069,000 11,494,000 -6,728,000   -4,909,000 7,670,000 -6,881,000 -5,411,000   -6,913,000 -6,362,000            -1,900,000 -2,992,000 7,813,000    997,000 774,813 -2,810,000 -1,999,000 1,572,000  
      cash and cash equivalents, beginning of period
    		0 0 87,928,000 0 0 0 169,681,000 0 0 0 14,602,000 0 0 0 21,304,000 0 0 0 49,224,000 0 0 0 20,733,000         -4 0 0 2,726,000 -477 0 0 5,495,000 -290 0 0 7,957,000 -230 
      cash and cash equivalents, end of period
    		170,165,000 -4,834,000 81,331,000 39,515,000 -8,611,000 14,177,000 42,847,000 117,244,000 33,069,000 11,494,000 7,874,000 -5,149,000 -4,314,000 -4,909,000 28,974,000 -6,881,000 -5,411,000 -8,011,000 41,607,000 -6,913,000 -6,362,000 47,429,000 15,070,000         11,452,507 -1,900,000 -2,992,000 10,539,000 -2,689,004 2,913,000 -3,990,000 6,492,000 774,523 -2,810,000 -1,999,000 9,529,000 7,892,710 
      supplemental disclosure of non-cash operating and financing information
    		                                            
      cash paid for interest
    		1,256,000 1,255,000 805,000                                          
      operating lease right-of-use assets obtained in exchange for operating lease obligations
    		   0    0 0                                    
      accrued clinical trial site costs
    		 39,000 -2,000 64,000 -101,000 -532,000 -998,000 156,000 -229,000 -65,000 309,000 396,000 -330,000 -365,000 101,000 -173,000 -334,000 -213,000 351,000 390,000 -45,000 598,000 847,000                      
      payment of deferred financing costs
    		                                            
      proceeds from exercise of common stock and pre-funded stock warrants
    		                                            
      net decrease in cash and cash equivalents
    		 -4,834,000 -6,597,000    -126,834,000     -5,149,000       -7,617,000    -5,663,000             -2,688,527 2,913,000        
      cash flows from investing activities
    		                                            
      purchases of property and equipment included in accounts payable
    		      8,000                                      
      noncash lease expense
    		                   73,000 73,000 69,000 68,000                      
      change in fair value of stock warrants
    		        653,000    -2,000 -2,000 -27,000 -139,000 -112,000 -56,000 -201,000 -5,105,000 689,000 -3,808,000 -3,413,000 7,894,000 -7,116,000 4,267,000 1,919,000 -2,071,000 -2,073,000 3,834,000 -212,000              
      proceeds from issuance of debt, net of issuance costs
    		                                            
      proceeds from the sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
    		                                            
      non-cash exercise of 2018 pipe warrants
    		                                            
      debt issuance costs included in accounts payable
    		                                            
      proceeds from the sale of common stock and common stock warrants, net of costs
    		                                            
      unpaid financing costs included in accounts payable and accrued liabilities
    		                                            
      proceeds received prior to and for the issuance of common stock
    		                                            
      supplemental disclosure of non-cash financing information
    		                                            
      unpaid financing costs included in accounts payable
    		                                            
      accretion of premium/discount on investments
    		      -473,000                                      
      change in fair value of common stock warrants
    		                                -130,000 90,000 69,000  -200,000 47,000 -1,170,000  -72,000 -4,925,000 6,174,000  
      proceeds from sale of common stock, common stock warrants and pre-funded stock warrants, net of issuance costs
    		                                            
      proceeds from exercise of common stock warrants and pre-funded stock warrants, net of costs
    		                                            
      proceeds from stock option exercises
    		       337,000            0 0                        
      supplemental disclosure of non-cash investing and financing information
    		                                            
      proceeds from sale of common stock and common stock warrants, net of issuance costs
    		                                            
      proceeds from sale of common stock and pre-funded warrants, net of costs
    		            342,000 -282,000 14,048,000                              
      proceeds from exercise of common stock warrants, net of costs
    		                                            
      proceeds from sale of common stock and common stock warrants, net of costs
    		                                            
      unpaid costs for issuing common stock and pre-funded warrants
    		              282,000                              
      gross proceeds from sale of common stock and common stock warrants
    		                                            
      payment of issuance costs
    		                                            
      principal paid on finance lease liabilities
    		               -5,000 0 2,000 -5,000 -4,000 -5,000 -4,000 -4,000                      
      right-of use assets obtained in exchange for operating lease obligations
    		                                            
      other assets
    		                                            
      supplemental disclosure of non-cash activities
    		                                            
      right-of-use assets obtained in exchange for operating lease obligations
    		                0                            
      deferred financing costs included in accounts payable
    		                                            
      purchases of property and equipment in accounts payable
    		                   -2,000                         
      prepaid expenses and other current assets
    		                        96,000 132,000 -74,000  47,000 175,000 -80,000              
      other long-term assets
    		                                   810         
      proceeds from sale of common stock, net of costs
    		                    -190,000                        
      purchase of property and equipment in accounts payable
    		                                            
      operating income of minority interest investment
    		                                            
      due from related party
    		                       9,000 9,000 54,000 -8,000                  
      security deposit on sublease
    		                       0                     
      security deposit received from expired lease
    		                                            
      proceeds from sale of minority interest investment in former subsidiary
    		                       0                     
      supplemental disclosure of non-cash investing information
    		                                            
      operating income on minority interest investment
    		                        123,000 165,000 190,000                  
      purchases of property and equipment with capital lease obligation
    		                                            
      financing costs in accounts payable and accrued liabilities
    		                                            
      income from discontinued operations
    		                           -130,000 -427,000 -423,000 -514,000 -544,575 -1,679,000            
      income from continuing operations
    		                       -14,625,000 889,000 -10,008,000 -7,030,000 393,000 -1,779,000 -7,214,000 -3,241,000 -4,480,850 -2,107,000            
      adjustments to reconcile net income from continuing operations to net cash from operating activities:
    		                                            
      gain on deconsolidation of former subsidiary
    		                                            
      net cash from continuing operating activities
    		                       -5,076,000 -4,719,000 -3,893,000 -3,687,000 -3,548,000 -2,273,000 -2,468,000 -2,033,000 -2,277,768 -1,122,000            
      net cash from discontinued operating activities
    		                           -188,000 -404,000 -282,000 -487,000  -1,149,000            
      net cash from continuing investing activities
    		                       103,000 441,000 -6,000 -10,000 -2,000 -5,000   15,002 -350,000            
      net cash from discontinued investing activities
    		                               224,780 721,000            
      net cash from continuing financing activities
    		                              -112,000 13,944,687 0            
      net cash from discontinued financing activities
    		                           0 700,000 425,000 400,000              
      net increase in cash and cash equivalents from continuing operations
    		                                            
      net decrease in cash and cash equivalents from discontinued operations
    		                                            
      supplemental disclosures of non-cash investing and financing information
    		                                            
      accrued liability for cost of issuing common stock
    		                                            
      warrants issued in connection with sale of common stock
    		                                            
      board fees paid with common stock
    		                        0 45,000 46,000 78,000 61,000 54,000 82,000 82,786 82,000 68,000 45,000          
      accrued compensation and other liabilities
    		                                            
      net decrease in cash, cash equivalents and restricted cash from continuing operations
    		                        -4,278,000 -3,899,000 -3,697,000                  
      net increase in cash, cash equivalents and restricted cash from discontinued operations
    		                            296,000                
      net decrease in cash, cash equivalents and restricted cash
    		                        -4,278,000 -3,899,000 -3,697,000                  
      net increase in cash and cash equivalents included in current assets held for sale
    		                            -372,000 -94,000 -2,000              
      cash, cash equivalents and restricted cash, beginning of period
    		                        0 0 23,099,000 0 0 0 17,135,000              
      cash, cash equivalents and restricted cash, end of period
    		                        -4,278,000 -3,899,000 19,402,000 12,860,000 -2,354,000 -2,308,000 14,901,000              
      accrued compensation and other current liabilities
    		                         123,000 49,000 -210,000 278,000 141,000 -252,000 -4,303 119,000 -239,000 46,000 255,808 -30,000 -372,000 -317,000      
      net decrease in cash, cash equivalents and restricted cash from discontinued operations
    		                              -87,000              
      cash paid for the issuance of common stock and common stock warrants
    		                                            
      income tax benefit
    		                                            
      non-cash expense of issuing shares to aspire capital
    		                                0 0 602,000          
      other long-term liabilities
    		                               -20,040 0 17,000 -37,000 -40,365 -12,000 -8,000 72,000      
      costs of essentialis acquisition paid
    		                                -350,000            
      proceeds from issuance of common stock
    		                               0 0 0 10,000,000          
      proceeds from sale of common stock and common stock warrants
    		                                            
      net increase in cash, cash equivalents and restricted cash from continuing operations
    		                           12,752,000 -2,278,000 -2,357,000 -2,145,000              
      net increase in cash, cash equivalents and restricted cash
    		                           12,392,000 -1,982,000 -2,214,000 -2,232,000              
      issuance of common stock in essentialis acquisition
    		                                0 -22,000 18,786,000          
      contingent consideration of essentialis acquisition
    		                                0 0 1,090,000          
      net cash from (used) in investing activities
    		                                            
      costs of essentialis acquisition included in accounts payable
    		                                            
      cash paid for the issuance cost of common stock and common stock warrants
    		                              -112,000              
      contingent cash consideration of essentialis acquisition
    		                                            
      costs of issuing common stock and common stock warrants recorded in accounts payable
    		                              91,000              
      loss on disposition of equipment
    		                                            
      inducement charge for series c warrants
    		                                       -625 0 0 3,050,000  
      noncash expense of issuing shares to aspire capital
    		                                            
      prepaid expenses and other assets
    		                               -197,356 100,000 16,000 -15,000 -28,928 -60,000 59,000 -49,000 57,630 86,000 -52,000 -7,000 -66,123 
      net cash from discontinued operations
    		                                            
      costs of essentialis acquisition
    		                                            
      purchase of property and equipment
    		                               1,431 0 0 -4,000 320 0 -20,000 -19,000 -7,777 -32,000 -15,000 -1,000  
      cash paid for the cost issuance of common stock and common stock warrants
    		                                            
      proceeds from exercise of common stock options
    		                                   102 0   -427 0 282,000 12,000  
      net proceeds from issuance of series a convertible preferred
    		                                            
      net proceeds from issuance of series b convertible preferred
    		                                            
      redemption of series a convertible preferred stock in conjunction with issuance of series b convertible preferred stock
    		                                            
      series a convertible preferred transaction costs paid
    		                                            
      net increase in cash and equivalents
    		                                            
      supplemental disclosure of cash flow information
    		                                            
      cash paid for income taxes
    		                                            
      supplemental disclosures of noncash investing and financing information
    		                                            
      issuance of common stock for essentialis acquisition
    		                                            
      conversion of series a preferred to common stock
    		                                   -1,020,000 0 555,000 1,665,000      
      conversion of series b preferred to common stock
    		                                  6,000          
      series b preferred convertible stock transaction costs included in accounts payable
    		                                            
      fixed asset purchases included in accounts payable
    		                                            
      de-recognition of series b warrant liability through cashless exercise
    		                                            
      loss on disposition of property & equipment
    		                                            
      proceeds from sale of series a preferred convertible stock
    		                                    0 0 5,071,000      
      series a preferred convertible stock transaction costs paid
    		                                    0 0 -71,000      
      proceeds from sale of series b preferred stock
    		                                            
      redemption of series a preferred stock in conjunction with issuance of series b preferred stock
    		                                            
      continuing operations
    		                                -1,471,000            
      discontinued operations
    		                                -429,000            
      de-recognition of series b warrant liability
    		                                        -1,000 0 6,748,000  
      series b preferred transactions costs in accounts payable
    		                                            
      fixed asset purchases in accounts payable
    		                                            
      costs of essentialis acquistions included in accounts payable
    		                                  572,000          
      benefit from deferred taxes
    		                                            
      acquisition of neoforce assets
    		                                            
      acquisition of bddi asset
    		                                            
      increase in restricted cash
    		                                       76,000 -76,000    
      proceeds from exercise of series a warrants
    		                                       0 0 0 156,000  
      proceeds from exercise of series b warrants
    		                                       -111,287 0 0 3,832,000  
      proceeds from issuance of common stock to aspire capital
    		                                            
      repayment of credit line
    		                                       471 0 0 -102,000  
      initial public offering costs paid
    		                                       -45,181 0 0 -530,000  
      series a preferred convertible stock transaction costs included in accounts payable
    		                                            
      de-recognition of series b warrant liability through cash exercise
    		                                            
      de-recognition of series a warrant liability through cash exercise
    		                                            
      bddi patent purchase consideration included in accrued liabilities
    		                                            
      shares issued as consideration for bddi patent purchase
    		                                            
      cashless exercise of 2010 and 2012 warrants
    		                                            
      contribution of series b warrants
    		                                            
      loss on disposition of property and equipment
    		                                    0       -273 
      cash paid for purchase of assets of neoforce group, inc.
    		                                            
      cash paid for patent acquisition
    		                                            
      proceeds from sale of series b preferred convertible stock
    		                                            
      redemption of series a preferred convertible stock in conjunction with issuance of series b convertible preferred
    		                                            
      proceeds from other exercise of series b warrants
    		                                        0 0 189,000  
      series b warrant transaction costs paid
    		                                        -131,000 0 -175,000  
      patent costs included in accrued liabilities
    		                                        -150,000    
      stock issuable in consideration for patent purchase
    		                                            
      de-recognition of series a warrant liability
    		                                        0 0 42,000  
      reduction in initial public offering costs payable
    		                                        0 0 45,000  
      cashless exercise of 2010/2012 warrants
    		                                        0 0 13,000  
      de-recognition of series b warrants contributed back to the company
    		                                        0 0 3,000  
      series b transaction costs in accounts payable
    		                                            
      series b warrant transaction costs included in accounts payable
    		                                            
      fixed asset costs included in accounts payable
    		                                      11,000      
      series b warrant transaction costs accrued and included in accrued compensation and other current liabilities
    		                                          131,000  
      non-cash interest expense relating to convertible promissory notes & amortization of discount on notes
    		                                            
      non-cash interest expense relating to line of credit
    		                                            
      other receivables
    		                                            
      accrued compensation & other current liabilities
    		                                            
      proceeds from issuance of series a convertible preferred
    		                                            
      proceeds from issuance of preferred stock warrants
    		                                            
      proceeds from issuance of convertible notes payable
    		                                           493,781 
      proceeds from line of credit
    		                                            
      proceeds from initial public offering
    		                                            
      initial public offering costs accrued and included in accounts payable
    		                                            
      beneficial conversion feature related to the warrants to purchase shares of convertible preferred stock in connection with convertible promissory notes
    		                                            
      issuance of warrants for the purchase of convertible preferred stock in connection with notes payable
    		                                            
      2014 notes payable converted into units in the ipo
    		                                            
      2010/2012 notes payable converted into common stock in conjunction with ipo
    		                                            
      amortization of intangible assets
    		                                            
      change in fair value of preferred stock warrants
    		                                            
      non-cash interest expense relating to warrants and convertible promissory notes
    		                                            
      inventories
    		                                        -98,000 -72,000 -97,000  
      accrued liabilities
    		                                        103,000 502,000 115,000  
      issuance of 50,000 shares of common stock as consideration for patent acquisition
    		                                            
      proceeds from sale of property and equipment
    		                                            
      issuance of restricted common stock in exchange for intellectual property
    		                                            
      proceeds from issuance of warrants
    		                                            
      deferred offering costs paid
    		                                            
      issuance of warrants in connection with notes payable
    		                                            
      beneficial conversion feature in connection with convertible promissory notes
    		                                            
      deferred offering costs accrued and included in accounts payable
    		                                            
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.